Terazosin

alpha-Adrenergic Blocker — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Terazosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1987. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 16 molecular targets, including ADRA1D, ADRA1B and Adra1a. Recorded indications include Benign prostatic hyperplasia and Hypertensive disorder.

• Approval status: ofp (first approved 1987 by the FDA).
• Drug class: alpha-Adrenergic Blocker.
• Mechanism of action: Adrenergic alpha-Antagonists.
• Molecular targets: ADRA1D, ADRA1B, Adra1a and ADRA1B (16 listed in DrugCentral).
• Indications: Benign prostatic hyperplasia and Hypertensive disorder.
• ATC code: G04CA03 (Alpha-adrenoreceptor antagonists).
• Molecular formula: C19H25N5O4; molecular weight 387.44 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Benign prostatic hyperplasia
• Hypertensive disorder

Contraindications (5)

• Cataract surgery
• Intraoperative floppy iris syndrome
• Orthostatic hypotension
• Priapism
• Syncope

Mechanism & targets

• Mechanism of action (MoA): Adrenergic alpha-Antagonists
• Established pharmacologic class: alpha-Adrenergic Blocker

Molecular targets (16)

Target	Gene	Action	Activity
Alpha-1D adrenergic receptor	ADRA1D	antagonist	Ki 9.20
Alpha-1B adrenergic receptor	ADRA1B	unknown	Ki 9.16
Alpha-1A adrenergic receptor	Adra1a	unknown	Ki 9.09
Alpha-1B adrenergic receptor	ADRA1B	antagonist	Ki 9.08
Alpha-1D adrenergic receptor	Adra1d	unknown	Ki 9.00
Alpha-1A adrenergic receptor	ADRA1A	antagonist	Ki 8.95
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 8.72
Alpha-2B adrenergic receptor	Adra2b	unknown	Ki 8.11
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 7.59
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.93
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.88
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.26
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 5.45
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 4.75
Solute carrier family 22 member 1	SLC22A1	unknown	IC50 4.63
Ribosyldihydronicotinamide dehydrogenase [quinone]	NQO2	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1987-08-07	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
G04CA03	GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hypotension	78.4
Hyperkalaemia	65.7
Acute kidney injury	48.9
Syncope	45.3
Blood pressure increased	44.4
Neoplasm skin	44.3
Bradycardia	44.2
Myocardial infarction	43.5
Asthenia	43.4
Vulvovaginal mycotic infection	38.8
Dizziness	37.9
Orthostatic hypotension	36.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Terazosin is on its molecule page.

• Molecular formula: C₁₉H₂₅N₅O₄
• Molecular weight: 387.44 g/mol
• CAS number: 63590-64-7
• InChIKey: VCKUSRYTPJJLNI-UHFFFAOYSA-N
• PubChem CID: 5401

COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Terazosin used for?

DrugCentral lists the following indications for Terazosin: Benign prostatic hyperplasia and Hypertensive disorder.

How does Terazosin work?

Terazosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include ADRA1D (antagonist), ADRA1B, Adra1a and ADRA1B (antagonist).

When was Terazosin first approved?

Terazosin was first approved by the FDA in 1987.

What drug class does Terazosin belong to?

Terazosin is in the alpha-Adrenergic Blocker class.

What is the chemical formula of Terazosin?

Terazosin has the molecular formula C19H25N5O4 and a molecular weight of 387.44 g/mol.

Sources

• DrugCentral drug card 3584 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201091 — compound record and bioactivity
• PubChem CID 5401 — chemical identifiers
• DrugBank DB01162 — drug record
• FDA UNII 8L5014XET7 — substance identity
• DailyMed: FDA labels for Terazosin — current prescribing information (label search)
• UniProt P25100 (ADRA1D) — target protein
• UniProt P35368 (ADRA1B) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P18089 (ADRA2B) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt P08913 (ADRA2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.